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Abstract 
 Regenerative medicine offers hope of a sustainable solution for severe airway disease by 
the creation of functional, immunocompatible organ replacements. When considering 
fetuses and newborns, there is a specific spectrum of airway pathologies that could benefit 
from cell therapy and tissue engineering applications. While hypoplastic lungs associated 
with congenital diaphragmatic hernia (CDH) could benefit from cellular based treatments 
aimed at ameliorating lung function, patients with upper airway obstruction could take 
advantage from a de novo tissue engineering approach. Moreover, the international 
acceptance of the EXIT procedure as a means of securing the precarious neonatal airway, 
together with the advent of fetal surgery as a method of heading off postnatal co-
morbidities, offers the revolutionary possibility of extending the clinical indication for tissue-
engineered airway transplantation to infants affected by diverse severe congenital 
laryngotracheal malformations. This chapter outlines the necessary basic components for 
regenerative medicine solutions in this potential clinical niche. 
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Clinical Background 
 
Tracheal failure is devastating in any patient group, but is particularly emotive within the 
neonatal population. Structural congenital anomalies (Table 1) are the most common cause 
of airway obstruction and insufficiency in this period [1], with malformations forming a 
spectrum of severity affecting any portion of the upper respiratory tract from face to bronchi 
[2]. Although complete congenital laryngotracheobronchial obstruction is rare - the 
European Organization for Rare Diseases reports the prevalence of tracheal agenesis to be 
around 1 in 100,000 births - these anomalies are universally lethal without intervention. 
 
Presentation and diagnosis of extreme laryngotracheal birth defects usually occurs following 
routine prenatal ultrasound scanning with confirmation by in utero MRI [3], but can present 
later with immediate respiratory distress at birth. Without immediate surgical intervention, 
the lack of a patent proximal airway is unsurvivable unless a bypassing pathway exists for 
intubation of the bronchi via associated broncho-oesophageal fistulae. Fortunately, rates of 
prenatal diagnosis are improving allowing planned delivery via the EXIT procedure, where a 
precarious neonatal airway may be salvaged or established de novo via anaesthetic 
techniques or tracheostomy prior to cutting the umbilical cord [4]. An increasing number of 
children are being born alive with previously ‘unsurvivable’ airway defects, with the clinical 
team’s intention to treat by subsequent airway reconstructive procedures (Figure 1). 
 
Anatomical malformations of the fetal trachea may occur in association with a constellation 
of other mediastinal abnormalities; cardiac, vascular and oesophageal malformations are 
particularly common. Definitive surgical correction of the trachea requires careful timing and 
coordination between otolaryngology, cardiothoracics, obstetrics, pediatric surgery and 
neonatal intensive care for maximal chances of survival [5]. In some cases, babies with 
proximal airway anomalies are also found to have an underlying chromosomal abnormality 
[6-8]. The argument for pre- and perinatal treatment of these children is even more 
nebulous given the potential presence of other underlying unsurvivable co-morbidities, and 
for this reason chromosomal and genetic testing via amniocentesis provides vital 
information for counseling parents on treatment options. 
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Despite perinatal intervention, death is sadly inevitable for many of these babies for two 
main reasons. The first of these is the in utero development of secondary severe congenital 
lung disease. Without a patent connection between mouth and lungs to provide a route of 
escape, the constant production of lung fluid overdistends the lungs throughout gestation, 
leading to congestive heart failure in the fetus (hydrops) [9]. In cases of extensive tracheo-
oesophageal connections or CDH, the opposite problem where babies are born with 
hypoplastic lungs may also occur because the fetus has been unable to generate intra-
pulmonary negative pressure in utero [10]. Fetal surgical techniques have gained acceptance 
in a variety of conditions including CDH [11, 12], and fetal tracheostomy is gaining 
momentum as a viable treatment option to relieve tracheal obstruction in some fetal 
surgical centers [13]. 
 
The second, as-yet insurmountable, obstacle to survival occurs if insufficient salvageable 
trachea exists to reconstruct a functional airway. Anterior augmentation surgery, for 
example using tracheal donor allografts [14], has been largely superseded by the highly 
successful slide tracheoplasty technique [15, 16], but resections are still limited to 30% of 
the total tracheal length [17]. Stents may be of help in cases of malacia and recurrent 
stenosis, but carry a large inherent morbidity [18]. Nevertheless, existing treatments fail or 
are insufficient in a small proportion of babies who therefore require whole-scale tracheal 
replacement. Tracheal replacement by conventional organ transplantation has generally not 
been possible in the neonatal setting, due to the paucity of appropriate-sized donor organs 
and the generally poor condition of donor tracheae following prolonged end-of-life 
intubation and ventilation [14]. The decision to subject a child to the accompanying lifelong 
immunosuppression with its multiple risks and comorbidities would also not be taken lightly. 
 
Concept of Tissue Engineering 
Tissue engineering unites the fields of cell biology, materials science and engineering 
towards a common goal of creating substitutes to repair, replace or regenerate tissues and 
organs [19]. The basic principle is to create a biocompatible scaffold in which growth of the 
patient’s cells can be encouraged, either by seeding prior to implantation or by subsequent 
recruitment into the scaffold in its in vivo position. The prerequisite for the graft to be free 
from immunogenicity is another key objective of tissue engineering as a personalized 
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therapy, and distinguishes the field from conventional transplantation where 
immunosuppression is required to prevent rejection. 
 
Tissue-engineered trachea could be of particular value in the context of a prenatal tracheal 
diagnosis because an organ replacement could be built to individual fetal dimensions during 
gestation, ready for use in the perinatal or immediate postnatal period (Figure 2). 
 
The trachea was initially considered, perhaps naively, to be a convenient ‘starter organ’ on 
which to concentrate tissue engineering efforts, due to its relatively simple anatomy as a 
hollow air-conduction organ with no moving parts [20]. However, early attempts in animals 
to replace the trachea with simple silicon, Dacron or metal [21, 22] tubes proved disastrous, 
as the trachea occupies a frontline immunological position with the body’s external 
environment. The pseudostratified ciliated epithelium of the proximal airways is highly 
specialized to trap and remove inhaled pathogens and debris, and lack of a functional 
mucociliary escalator post-transplantation is therefore highly problematic. Establishment of 
a blood supply is essential for epithelialization of any graft, but with a finely segmental 
native blood supply in place of a vascular pedicle amenable to anastomosis, bioengineered 
tracheal grafts are relatively slow to establish connections capable of supporting cell growth 
and integration with host tissues. Notwithstanding these issues, tracheal tissue engineering 
raises fewer potential ethical objections as an experimental therapy than in other clinical 
niches, given the total lack of alternative treatment options, and the greater intrinsic 
regenerative potential of pediatric patients compared to adults increases the likelihood of 
success. As such, regenerative approaches in the trachea have outstripped other organs in 
terms of high profile clinical compassionate cases both in adults [23], and in children [24, 25]. 
 
Organ Scaffolds 
Scaffold design, to create a framework on which cells can engraft and differentiate, is a core 
component of tissue engineering. Scaffold constructs provide structural and functional cues 
for the regenerative process and should allow for sustained integration when transplanted. 
An ideal scaffold for airway transplantation would be: 
 inert, non-carcinogenic and non-immunogenic; 
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 biocompatible and capable of promoting cell engraftment, proliferation and 
differentiation; 
 mimic the macroscopic and microscopic architecture of airway region being replaced;  
 mechanically stable and resistant to collapse following transplantation; 
 able to rapidly recapitulate a vascular system; 
 readily available. 
 
More specifically for a neonate or child, the scaffold needs to accommodate significant 
growth and adapt to developmental requirements. A neonatal trachea is typically 5 cm in 
length and 5 mm in diameter and grows 5mm a year to full adult length of approx. 15 cm 
and 20 mm diameter at 16 years of age [26]. The ultimate aim of tissue engineering is to 
create an organ that grows with the child, thereby avoiding multiple surgeries to transplant 
upsized replacements. Integration of the scaffold into the surrounding host tissue by 
remodeling and regeneration (rather than by stenotic scarring) is a final key aim, and is 
particularly pertinent in pediatric airway surgery where serial dilation of stenosis forms a 
large part of the surgical workload. 
 
The optimal scaffold material is still a subject of debate and may vary depending on the 
specific clinical indication [27]. A variety of scaffold materials have been tested for airway 
transplantation which have been traditionally classified into two types, namely those 
derived from native biological material [28]  and those that are wholly synthetic [29]. 
Biological scaffolds are created from native tissues and organs, through a decellularisation 
process whereby resident cells are disrupted and removed using mechanical forces, 
nucleases, and/or detergents in combination or in repeated cycles. The resulting product is a 
bare extracellular matrix framework derived from the original tissue or organ that is devoid 
of the immunogenic cell epitopes normally found in allografts. For the airway, these 
decellularised scaffolds offer a significant advantage over other materials in that they are 
closely biomimetic, retaining both macro- and microscopic architecture. Increasing evidence 
suggests that functional cues are also retained in the form of small molecular proteins within 
both tracheal and lung matrix promoting differentiation of engrafted cells [24, 30, 31]. 
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Whilst the benefits of decellularised tissues and organs are undisputed, these scaffolds are 
dependent on donors; as in adult allotransplantation, the supply of neonatal and pediatric-
sized tissues and organs are also severely limited [32]. Despite those limitations, 
decellularised tissue has lead to clinical translation of tissue engineered airways with worse 
outcome associated to the use of synthetic materials, particularly in pediatrics [33]. 
Alternative donor sources, such as scaffolds derived from xenografts, may be promising 
substitutes [34]; however, this strategy comes with its own hurdles, such as the difficulties of 
ensuring that the xenograft is a suitable anatomical substitute, the potential for zoonotic 
infections, and the possibility for long-term scaffold rejection due to xenospecific epitopes 
[35]. 
 
Synthetic scaffolds may overcome these problems in the future, but current technology 
limits scaffold design being matched for macroscopic features only. Furthermore synthetic 
scaffolds for neonates and children are again limited by the need to accommodate growth 
leading to the necessity of multiple operations. Early work has begun to address this with 
the utilization of biodegradable material to create scaffolds that aim to be completely 
replaced by recipient tissue. Materials developed so far have been shown to be 
biocompatible and were able to support extracellular matrix formation in engineered 
cartilage in an animal model [36, 37]. Future scaffold development may ultimately combine 
the best of both decellularised and synthetic strategies to create composite or hybrid 
constructs.  
 
Other considerations specific for airway tissue engineering applications are the scaffold 
requirements for the anatomical region of interest. The trachea, as a tubular hollow organ 
construct, is often considered a simple structure to recreate; however the remaining parts of 
the airway are infinitely more challenging. The larynx has the added complexity of requiring 
fine motor control for vocal cord function; for a fully functional organ replacement, 
engineering for vocal cord ‘moving parts’, either by surgical reinnervation, or by using soft 
robotic ‘pacing’ implants will be required for voice, swallow and airway protection. 
Nevertheless, initial attempts to engineer laryngeal muscle and cartilage have shown 
promising results. Halum et al implanted synthetic PCL constructs into surgically created 
hemi-larynx defects in rats, and saw that implants seeded with muscle progenitor cells 
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differentiated to express motor end plates demonstrated local neuronal growth and bursts 
of motor unit potentials with a similar firing timing and intensity to the contralateral native 
adductor muscle complex, whilst implants seeded with undifferentiated muscle progenitor 
cells or myotubules did not [38]. Jacobs et al performed laryngotracheal reconstructions in 
rabbits using tissue-engineered cartilage consisting of 1% hyaluronic acid constructs seeded 
with autologous auricular chondrocytes, crosslinked by UV photopolymerisation following 
seeding. Thirteen out of 15 animals receiving such grafts survived to 12 weeks, and the 
tissue-engineered cartilage functioned well with similar epithelialisation, chondrocyte 
survival, mechanical strength and histology to control cartilage [39]. The full-scale phase I/II 
RegenVOX clinical trial to implant autologous stem-cell-seeded decellularised hemilarynges 
are currently in progress in the UK to assess this therapy’s efficacy and safety in adult 
patients with severe acquired laryngotracheal stenosis [27]. 
 
Recellularisation of Bioengineered Airway 
The functionality of tissues in vivo relies heavily upon the presence of a range of 
differentiated cell types. In the airways, chondrocytes populate cartilage to provide 
structural support whilst an epithelial layer lines the luminal surface, allowing clearance via 
the mucociliary escalator [40]. Ideally, tissue-engineered airway transplantation strategies 
should incorporate methods to restore these functions as quickly as possible following 
surgery to minimize the risk of airway collapse or infection [31, 41]. 
 
In the pediatric setting, the use of autologous cells to restore tissue function is of particular 
importance in order to avoid the need for lifelong immunosuppression. However, in fetal or 
neonatal cases, access to autologous tissue to extract these cells poses a challenge. 
Practically, the amniotic fluid represents a source of prenatal cells with great promise. Our 
laboratory and others have shown that stem cells can be isolated from human amniotic fluid 
[42] and that these cells can be reprogrammed to pluripotency, i.e. gain the potential to 
differentiate into all cell lineages [43, 44]. Cells could be isolated prenatally, reprogrammed 
and driven towards the cell lineages of interest for airway bioengineering for application in 
neonatal procedures. The time taken to generate iPSCs and subsequent tissue-specific 
derivatives is considered a major hurdle to translation of these techniques [45] but this may 
be less critical in neonatal procedures where the diagnosis is usually made early in gestation, 
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typically at around 21 weeks, several months before a therapeutic approach is usually 
needed.  
 
IPSC technology continues to improve at a rapid rate but much work remains to improve the 
safety profile of cultured cells for transplantation [46]. A second strategy to generate 
autologous epithelial cells for airway bioengineering from amniotic fluid is to culture cells 
directly. Fetal epithelia, including the respiratory tract, are in contact with amniotic fluid, 
which contains a variety of poorly characterized epithelial cell types [47-49]. Further, 
advances in surgical techniques mean that it is now also possible to obtain tracheal aspirates 
[50], which may contain a higher abundance of respiratory progenitors and would be 
particularly valuable in patients with congenital high airways obstruction syndrome (CHAOS) 
whose obstruction may impede shedding of respiratory cells into the bulk amniotic fluid. 
    
Any strategy reliant upon amniotic fluid as a cell source depends on early prenatal diagnosis 
but in cases presenting postnatally, autologous tissue is more readily accessible. iPSCs 
derived from human dermal fibroblasts differentiate to form both proximal and distal airway 
epithelial cell types under culture conditions which mimic developmental processes [51-55]. 
Given that iPSCs can also generate chondrocytes [56, 57], these may represent an 
opportunity to generate from one original cell, multiple autologous cell types for airway 
transplantation.  
 
Endogenous airway stem cells represent an alternative postnatal cell source. Basal epithelial 
cells are tissue-specific stem cells that regenerate differentiated goblet cells, which produce 
airway mucus, and ciliated cells, which create motile force to move mucus across the 
epithelial surface [58, 59]. Basal epithelial cell cultures can be generated from endobronchial 
biopsies and recent work in our laboratory suggests that under optimized culture conditions 
these can multiply sufficiently in culture for bioengineering applications (Butler et al., in 
press). Currently, bone marrow-derived mesenchymal stromal cells (MSCs) represent the 
predominant source of autologous cartilage for postnatal tissue engineering as a result of 
the limited in vitro expansion potential of chondrocytes [60]. The use of MSCs in tissue-
engineered grafts may also provide beneficial immunomodulatory effects, anti-apoptotic 
effects and/or stimulate ingrowth of the host cells surrounding the graft [61].  
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Conclusions/Perspectives 
Despite considerable logistical and technical obstacles, airway tissue engineering is rapidly 
emerging as a serious potential therapy in adults. The potential for application of this 
technology to the fetal and neonatal population is particularly encouraging, as the ability to 
surgically correct serious airway malformations at an early stage may be able to considerably 
improve survival and surgical outcomes in the area of congenital airway disease.  
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Table 1: Examples of congenital anomalies leading to severe pediatric airway insufficiency. 
  
Anomaly Examples of Conditions 
Congenital High Airway Obstruction 
Syndrome (CHAOS) 
- Laryngeal or tracheal agenesis 
- Laryngeal webs or cysts 
- Congenital neck masses e.g. cystic 
hygromas, teratomas 
Abnormal aerodigestive tract connections - Type IV laryngeal clefts 
-  Tracheo-oesophageal fistulae 
Extrinsic mediastinal compression - Vascular ring or sling 
Stenosis of the trachea and/or bronchi - Complete tracheal rings 
Poor tracheal quality - Tracheomalacia (in isolation or 
downstream of airway stenosis) 
12 
 
Figure 1: Severe congenital airway defects A) Laryngeal agenesis viewed at bronchoscopy. B) 
Type IV laryngeal cleft viewed at open repair surgery. 
 
Figure 2: Concept schematic for a fetal/neonatal airway tissue engineering strategy 
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